Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 2, Pages 419-428Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2015.1043546
Keywords
Burkitt leukemia; lymphoma; Marsdenia tenacssima; Tenacigenoside A; tenacigenin B; Raji cells; BCL2; BCL-XL; BID
Categories
Funding
- Top Six Elite Scholar Program of Jiangsu Province China [2009-47-D]
- Jiangsu Provincial Administration of traditional Chinese medicine
Ask authors/readers for more resources
Burkitt lymphoma is a fast growing non-Hodgkin lymphoma that occurs primarily in young males. The causes of Burkitt lymphoma include chromosome rearrangement and virus infection, but accurate and complete reasons remain to be discovered. The available treatment for Burkitt lymphoma is chemotherapy and radiation therapy. It is a highly aggressive B-cell neoplasm with not all patients cured, in spite of current therapies. This study evaluated the effects of traditional Chinese medicine Marsdenia tenacssima (MTE) and its component compound Tenacigenoside A (TGTA) and 11-O-benzoyl-12-O-acetyltenacigenin B (TGTB) on human Burkitt lymphoma growth. It was observed that MTE, TGTA or TGTB inhibited cell growth and induced apoptosis of Burkitt lymphoma cells in culture. In lymphoma bearing NOD/SCID nude mice, both TGTA and TGTB inhibited tumor growth and improved animal survival. TGTA and TGTB significantly increased tumor cell apoptosis on lymphoma bearing mice, primarily through down-regulation of BCL2 and BCL-XL and up-regulation of BID.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available